Methodological challenges in assessing the impact of comorbidities on costs in Alzheimer's disease clinical trials.

ABSTRACT:

Background

Alzheimer's disease (AD) is associated with considerable costs and has a significant impact on health and social care systems.

Objective

This study assessed whether baseline comorbidities present in 2,594 patients with AD participating in two semagacestat randomized placebo-controlled trials (RCTs) would significantly impact overall costs.

Methods

Resource utilization was captured using the Resource Utilization in Dementia Scale-Lite. Comorbidities and concomitant medications were tabulated via patient and caregiver reports. Only baseline data were analyzed. Direct and indirect costs per month were calculated per patient. The relationship between cost and explanatory variables was explored in a regression model.

Results

The baseline monthly cost of c

SUBMITTER: Kahle-Wrobleski K 

PROVIDER: S-EPMC4646926 | biostudies-literature | 2015 Dec

REPOSITORIES: biostudies-literature